Clinical use of HIV-1 resistance genotyping.: Predictive factors of poor virological evolution in salvage treatments

被引:0
|
作者
Riera-Jaume, Melcior
Peñaranda-Vera, Maria
Angels Ribas-Blanco, Ma.
Murillas-Angoiti, Javier
Campins, Antoni
Salas-Aparicio, Ana
Leyes-García, María
Pareja-Bezares, Antonio
Pérez, José Luis
Villalonga-Pieras, Concepción
机构
[1] Hosp Univ Son Dureta, Unidad Enfermedades Infecciosas, Med Interna Serv, Palma de Mallorca 07014, Spain
[2] Hosp Son Llatzer, Serv Med Prevent & Epidemiol, Palma de Mallorca, Spain
[3] Hosp Son Dureta, Microbiol Serv, Palma de Mallorca, Spain
来源
关键词
antiretroviral treatment; salvage treatment; HIV infection; antiviral drug resistance; antiviral sensitivity testing;
D O I
10.1016/S0213-005X(06)73767-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
OBJECTIVES. To describe the use of genotype resistance testing (GRT) for virological failure in clinical practice, and the long-term clinical and virological evolution in patients for whom it is requested. To identify the predictive factors of virological failure in patients with antiretroviral (ARV) salvage therapy. METHODS. Observational study in HIV-infected patients for whom GRT was requested for virological failure (VF) in the period of 1 October 1999 to 31 December 2001. Logistic regression analysis was used to determine the predictive factors of virological progression. RESULTS. Over the period studied, 196 patients required GRT for VF (15%) among those monitored in specific units. GRT was mainly requested for patients who had been extensively pretreated for a mean of 5 years and with a median of 5 ARV combinations. Half the patients presented 3 or more mutations associated with thymidine analogs (TAMs), mutations associated with non-nucleoside analogs (NNRTIs), and 5 or more mutations associated with protease inhibitors (Pis). In 143 (74%) patients, the RTV regimen was changed on the basis of GRT results. In the intent-to-treat analysis, the percentage of patients with plasma VL < 400 cop/mL at 6,12 and 18 months was 41%,29% and 17%, respectively. In the on-treatment analysis, the results were 50%,48% and 46%, respectively. Mean CD4 lymphocyte increase was 59.74 and 94 cells/mm(3). The variables predicting virological failure (plasma VL > 400 cop/ml) at 12 months were plasma VL > 30,000 cop/mL (OR 6,1.8-19.5) and accumulation of 3 or more TAMs (OR 4.4, 1.3-15) at the start of ARV salvage therapy. CONCLUSION. Even though in clinical practice GRT is requested for patients with various treatment failures, when ART salvage treatment was started, plasma VL was undetectable and immunological response persisted in 40% of patients followed-up for 18 months. The factors best predicting virological evolution were VL and the number of baseline TAMs.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 50 条
  • [41] Long-term clinical and viro-immunological outcomes of Argenta, a randomized trial on the usefulness of HIV-1 drug resistance genotyping and expert advice
    Cingolani, A
    Di Giambenedetto, S
    Bacarelli, A
    Murri, R
    Ammassari, A
    Cauda, R
    De Luca, A
    ANTIVIRAL THERAPY, 2003, 8 (03) : U106 - U107
  • [42] Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings
    Armenia, Daniele
    Bouba, Yagai
    Gagliardini, Roberta
    Gori, Caterina
    Bertoli, Ada
    Borghi, Vanni
    Gennari, William
    Micheli, Valeria
    Callegaro, Anna Paola
    Gazzola, Lidia
    Bruzzone, Bianca
    Giannetti, Alberto
    Mazzotta, Valentina
    Vergori, Alessandra
    Mastrorosa, Ilaria
    Colafigli, Manuela
    Lichtner, Miriam
    di Biagio, Antonio
    Maggiolo, Franco
    Rizzardini, Giuliano
    Monforte, Antonella D'Arminio
    Andreoni, Massimo
    Mussini, Cristina
    Antinori, Andrea
    Ceccherini-Silberstein, Francesca
    Perno, Carlo Federico
    Santoro, Maria Mercedes
    JOURNAL OF CLINICAL VIROLOGY, 2020, 130
  • [43] Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance
    Billong, Serge C.
    Fokam, Joseph
    Aghokeng, Avelin F.
    Milenge, Pascal
    Kembou, Etienne
    Abessouguie, Ibile
    Meva'a-Onglene, Flore Beatrice
    Bissek, Anne C. Zoung-Kanyi
    Colizzi, Vittorio
    Mpoudi, Eitel N.
    Elat, Jean-Bosco N.
    Shiro, Koulla S.
    PLOS ONE, 2013, 8 (08):
  • [44] Evolution of HIV-1 Resistance to the Fusion Inhibitor C34-CXCR4 and Potential Fitness Costs in Consideration of a Phase 1 Clinical Trial
    Leslie, George J.
    Haggarty, Beth
    Romano, Josephine
    Jordon, Andrea P. O.
    Wang, Jianbin
    Richardson, Max W.
    Riley, James L.
    Holmes, Michael C.
    Tebas, Pablo
    Hoxie, James
    MOLECULAR THERAPY, 2017, 25 (05) : 303 - 303
  • [45] Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection
    Monforte, AD
    Testa, L
    Adorni, F
    Chiesa, E
    Bini, T
    Moscatelli, GC
    Abeli, C
    Rusconi, S
    Sollima, S
    Balotta, C
    Musicco, M
    Galli, M
    Moroni, M
    AIDS, 1998, 12 (13) : 1631 - 1637
  • [46] Open ORIGINAL RESEARCH Risk Factors of Drug Resistance and the Potential Risk of HIV-1 Transmission of Patients with ART Virological Failure: A Population-Based Study in Sichuan, China
    Zhou, Chang
    Kang, Rui
    Liang, Shu
    Fei, Teng
    Li, Yiping
    Su, Ling
    Li, Ling
    Ye, Li
    Zhang, Yan
    Yuan, Dan
    INFECTION AND DRUG RESISTANCE, 2021, 14 : 5219 - 5233
  • [47] A Pragmatic Approach to HIV-1 Drug Resistance Determination in Resource-Limited Settings by Use of a Novel Genotyping Assay Targeting the Reverse Transcriptase-Encoding Region Only
    Aitken, Susan C.
    Bronze, Michelle
    Wallis, Carole L.
    Stuyver, Lieven
    Steegen, Kim
    Balinda, Sheila
    Kityo, Cissy
    Stevens, Wendy
    de Wit, Tobias F. Rinke
    Schuurman, Rob
    JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (06) : 1757 - 1761
  • [48] Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry
    Armenia, Daniele
    Spagnuolo, Vincenzo
    Bellocchi, Maria C.
    Galli, Laura
    Duca, Leonardo
    Marchegiani, Greta
    Clemente, Tommaso
    Carioti, Luca
    Lolatto, Riccardo
    Calza, Leonardo
    Celesia, Benedetto M.
    Cascio, Antonio
    Francisci, Daniela
    Saracino, Annalisa
    Torti, Carlo
    Zazzi, Maurizio
    Castagna, Antonella
    Santoro, Maria M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (09) : 2354 - 2363
  • [49] An audit of proviral HIV-1 DNA genotypic resistance assay use in routine clinical practice: experience from an inner-city centre
    Wong, A. K. C.
    Kohli, M.
    Paraskevopoulou, S. M.
    Waters, L.
    HIV MEDICINE, 2021, 22 : 67 - 68
  • [50] HIV-1 pretreatment drug resistance in vertically infected children is associated with poor virological response to protease inhibitor (PI)-based first-line antiretroviral therapy (ART): results from a cohort study in Argentina
    Rozenszajn, Mijael
    Arazi-Caillaud, Solange
    Taicz, Moira
    Bologna, Rosa
    Mangano, Andrea
    Aulicino, Paula C.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (07) : 1969 - 1973